Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen.

Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen.

CAMPATH-1 antibodies recognise a unique molecule on human lymphocytes and are unusually efficient at causing cell lysis with homologous complement. They have been successfully used for lymphocyte depletion in vivo in a variety of diseases. The antigen is a small glycosylphosphatidylinositol (GPI)-an...

Full description

Bibliographic Details
Main Authors:	Xia, M, Hale, G, Waldmann, H
Format:	Journal article
Language:	English
Published:	1993

Similar Items

The CAMPATH-1 antigen (CDw52).
by: Hale, G, et al.
Published: (1990)

Characterization of the CAMPATH-1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone.
by: Xia, M, et al.
Published: (1991)

Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis.
by: Xia, M, et al.
Published: (1993)

Importance of antigen specificity for complement-mediated lysis by monoclonal antibodies.
by: Bindon, C, et al.
Published: (1988)

COMPLEMENT LYSIS MEDIATED BY ENGINEERED MULTIPLE-DOMAIN FORMS OF THE THERAPEUTIC ANTIBODY CAMPATH-1H
by: Greenwood, J, et al.
Published: (1994)

Therapeutic potential of monoclonal antibodies to the leukocyte-common antigen. Synergy and interference in complement-mediated lysis.
by: Bindon, C, et al.
Published: (1985)

Engineering multiple-domain forms of the therapeutic antibody CAMPATH-1H: effects on complement lysis.
by: Greenwood, J, et al.
Published: (1994)

Synergistic complement lysis by monoclonal antibodies to the human leukocyte common antigen requires both the classical and alternative pathways.
by: Bindon, C, et al.
Published: (1987)

Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G.
by: Williams, R, et al.
Published: (2000)

Peripheral blood dendritic cells express CD52 and are depleted in-vivo by treatment with CAMPATH-1H.
by: Buggins, A, et al.
Published: (2001)

Crystal structures of a rat anti-CD52 (CAMPATH-1) therapeutic antibody Fab fragment and its humanized counterpart.
by: Cheetham, G, et al.
Published: (1998)

Pilot study of CAMPATH-1, a rat monoclonal antibody that fixes human complement, as an immunosuppressant in organ transplantation.
by: Hale, G, et al.
Published: (1986)

T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation.
by: Hale, G, et al.
Published: (1988)

CAMPATH: from concept to clinic.
by: Waldmann, H, et al.
Published: (2005)

Specificity of monoclonal antibody Campath-1.
by: Hale, G, et al.
Published: (1988)

Availability of Campath-1 antibodies for bone marrow transplantation.
by: Hale, G, et al.
Published: (1995)

CAMPATH-1 monoclonal antibodies in bone marrow transplantation.
by: Hale, G, et al.
Published: (1994)

CAMPATH-1 antibodies in stem-cell transplantation.
by: Hale, G, et al.
Published: (2001)

CAMPATH-1H in inflammatory arthritis.
by: Watts, R, et al.
Published: (1993)

1.9 A structure of the therapeutic antibody CAMPATH-1H fab in complex with a synthetic peptide antigen.
by: James, L, et al.
Published: (1999)

A mu SR study of the CDW in TTF-TCNQ
by: Marshall, I, et al.
Published: (2001)

Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection.
by: Hale, G, et al.
Published: (1996)

Ex vivo T-cell depletion with the monoclonal antibody Campath-1 plus human complement effectively prevents acute graft-versus-host disease in allogeneic bone marrow transplantation.
by: Heit, W, et al.
Published: (1986)

Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?
by: Chakrabarti, S, et al.
Published: (2004)

T-CELL DEPLETION BY EXPOSURE TO CAMPATH-1G IN-VITRO PREVENTS GRAFT-VERSUS-HOST DISEASE
by: Jacobs, P, et al.
Published: (1994)

Prevention of immune-mediated corneal graft destruction with the anti-lymphocyte monoclonal antibody, CAMPATH-1H.
by: Newman, D, et al.
Published: (1995)

Leukaemic relapse after Campath 1-treated bone-marrow transplantation for leukaemia.
by: Waldmann, H, et al.
Published: (1987)

CAMPATH-1 MOAB IN THE TREATMENT OF REFRACTORY AUTOIMMUNE THROMBOCYTOPENIC PURPURA (ATP)
by: Lim, S, et al.
Published: (1993)

Campath-1 Abs 'in the bag' for hematological malignancies: the Cape Town experience.
by: Novitzky, N, et al.
Published: (2004)

T cell depletion by exposure to Campath-1G in vitro prevents graft-versus-host disease.
by: Jacobs, P, et al.
Published: (1994)

Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users.
by: Hale, G, et al.
Published: (1998)

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).
by: Lundin, J, et al.
Published: (2002)

HLA restriction of cell-mediated lysis of influenza virus-infected human cells.
by: Mcmichael, A, et al.
Published: (1977)

CAMPATH-1 monoclonal antibody therapy in severe refractory autoimmune thrombocytopenic purpura.
by: Lim, S, et al.
Published: (1993)

ISOTYPE VARIANTS OF CAMPATH-1 ANTIBODY - REQUIREMENTS FOR EFFECTIVE ANTIBODY ACTION INVIVO
by: Dyer, M, et al.
Published: (1989)

TREATMENT OF RHEUMATOID-ARTHRITIS WITH HUMANIZED ANTILYMPHOCYTE ANTIBODY CAMPATH-1H
by: Watts, R, et al.
Published: (1992)

Campath-1H therapy in refractory ocular inflammatory disease.
by: Dick, A, et al.
Published: (2000)

Sustained remission of severe resistant autoimmune neutropenia with Campath-1H.
by: Killick, S, et al.
Published: (1997)

Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
by: Hale, G, et al.
Published: (2002)

CAMPATH-IH in multiple sclerosis.
by: Moreau, T, et al.
Published: (1996)